Bicycle Therapeutics (BCYC) Consolidated Net Income (2018 - 2026)
Bicycle Therapeutics (BCYC) posted Consolidated Net Income of -$60.8 million for Q1 2026, down 129.75% on a QoQ basis from $204.5 million in Q4 2025, and little changed year-over-year from -$60.9 million in Q1 2025.
Bicycle Therapeutics (BCYC) Consolidated Net Income (2018 - 2026) Analysis & Trends
Bicycle Therapeutics' Consolidated Net Income history runs 9 years deep, the most recent figure standing at -$60.8 million for Q1 2026.
- Quarterly Consolidated Net Income changed 0.12% year-over-year to -$60.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 102.73% YoY) and the FY2025 annual result came in at $5.6 million, up 103.34% from the prior year.
- Consolidated Net Income was -$60.8 million for Q1 2026 at Bicycle Therapeutics, down from $204.5 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $204.5 million in Q4 2025 and bottomed at -$79.0 million in Q2 2025.
- A 5-year average of -$19.8 million and a median of -$39.8 million in 2024 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2023 — Consolidated Net Income jumped 517.79% — and 2024, when it sank 138.72%.
- Bicycle Therapeutics' Consolidated Net Income stood at -$32.0 million in 2022, then soared by 517.79% to $133.8 million in 2023, then sank by 138.72% to -$51.8 million in 2024, then surged by 494.55% to $204.5 million in 2025, then sank by 129.75% to -$60.8 million in 2026.
- Business Quant data shows BCYC's Consolidated Net Income at -$60.8 million in Q1 2026, $204.5 million in Q4 2025, and -$59.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Bicycle Therapeutics | 272.11 Mn | 272.11 Mn | - | -60.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.83 Mn |
| Dec 31, 2025 | 204.45 Mn |
| Sep 30, 2025 | -59.10 Mn |
| Jun 30, 2025 | -78.98 Mn |
| Mar 31, 2025 | -60.75 Mn |
| Dec 31, 2024 | -51.82 Mn |
| Sep 30, 2024 | -50.80 Mn |
| Jun 30, 2024 | -39.80 Mn |
| Mar 31, 2024 | -26.51 Mn |
| Dec 31, 2023 | 133.84 Mn |
| Sep 30, 2023 | -49.93 Mn |
| Jun 30, 2023 | -42.60 Mn |
| Mar 31, 2023 | -39.08 Mn |
| Dec 31, 2022 | -32.04 Mn |
| Sep 30, 2022 | -28.39 Mn |
| Jun 30, 2022 | -26.88 Mn |
| Mar 31, 2022 | -27.58 Mn |
| Dec 31, 2021 | -17.99 Mn |
| Sep 30, 2021 | -14.69 Mn |
| Jun 30, 2021 | -17.87 Mn |